London close: Stocks slip as US jobless claims rise
20th Feb 2025 16:06
(Sharecast News) - London equities ended lower on Thursday as investors reacted to a higher-than-expected rise in US jobless claims and a decline in UK consumer confidence.
Read moreUBS ups rating on AstraZeneca to 'buy'
13th Feb 2025 11:18
(Sharecast News) - UBS has upgraded AstraZeneca to a 'buy', citing the London-listed pharmaceutical firm's "sector-leading" drug pipeline.
Read moreMorgan Stanley sees huge upside at AstraZeneca
12th Feb 2025 10:21
(Sharecast News) - Morgan Stanley has initiated coverage of pharma giant AstraZeneca with an 'overweight' rating, recommending investors to build positions at a "compelling entry point".
Read moreRevenues, profits surge at AstraZeneca
6th Feb 2025 08:00
(Sharecast News) - AstraZeneca posted forecast-beating numbers on Thursday, fuelled by strong demand for its cancer and cardiometabolic drugs.
Read moreAstraZeneca's Imfinzi set for go-ahead by EU to treat lung cancer
3rd Feb 2025 07:02
(Sharecast News) - AstraZeneca's Imfinzi has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based chemoradiation therapy.
Read moreAstraZeneca's Enhurtu gets new US approval
28th Jan 2025 07:03
(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu has been approved in the US for the treatment of adults with HER2 breast cancer, after disease progression having had one or more hormone therapies.
Read moreAstraZeneca gets first US approval for cancer treatment Datroway
20th Jan 2025 07:30
(Sharecast News) - AstraZeneca announced on Monday that it has secured approval from the US Food and Drug Administration, alongside Daiichi Sankyo, for 'Datroway', or datopotamab deruxtecan, a treatment for adult patients with previously treated, unresectable or metastatic hormone receptor-positive, HER2-negative breast cancer.
Read moreAstraZeneca's rare cancer drug Calquence gets US regulatory nod
17th Jan 2025 07:13
(Sharecast News) - AstraZeneca has announced that its Calquence drug has been approved in the US when used alongside chemoimmunotherapy for patients with previously untreated mantle cell lymphoma (MCL).
Read moreLondon close: Stocks mixed in quiet post-Christmas trade
27th Dec 2024 14:38
(Sharecast News) - London markets closed on a mixed note Friday in subdued trading, as the ongoing holiday period kept activity light with little news to influence sentiment.
Read moreAstraZeneca pulls EU application for cancer drug
24th Dec 2024 07:09
(Sharecast News) - AstraZeneca has pulled its European marketing authorisation application for its non-small cell lung cancer treatment based on the results of a phase III trial.
Read moreAstraZeneca lung cancer drug Tagrisso approved by EU regulators
23rd Dec 2024 07:17
(Sharecast News) - AstraZeneca's lung cancer treatment Tagrisso has been approved by European Union regulators on the back of "powerful results" from a phase III trial.
Read moreAstraZeneca cancer drug secures US approval
5th Dec 2024 08:48
(Sharecast News) - AstraZeneca drug Imfinzi has been approved for use in the US for patients with limited stage small cell lung cancer, the biopharmaceutical specialist confirmed on Thursday.
Read moreAstraZeneca appoints Iskra Reic as vice-president of intl unit
4th Dec 2024 14:00
(Sharecast News) - AstraZeneca said it had appointed AstraZeneca today announced the appointment of Iskra Reic as Executive Vice President (EVP), International with responsibility for overall strategy and driving sustainable growth across this broad region. This encompasses China, Asian and Eurasian markets, Middle East & Africa, Latin America, Australia & New Zealand. as executive vice-president of its international division with responsibility for overall strategy and driving sustainable growth across China, Asian and Eurasian markets, Middle East & Africa, Latin America, Australia & New Zealand.
Read moreAstraZeneca reports positive results from prostate cancer trial
25th Nov 2024 07:17
(Sharecast News) - AstraZeneca announced positive results from a phase three prostate cancer trial on Monday, reporting that its AKT inhibitor 'Truqap', or capivasertib, in combination with abiraterone and androgen deprivation therapy (ADT), significantly improved radiographic progression-free survival (rPFS) in patients with PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC).
Read moreAstraZeneca's Tagrisso recommended for EU approval
18th Nov 2024 09:11
(Sharecast News) - Drugmaker AstraZeneca said on Monday that its Tagrisso asset had received a recommendation for EU approval on the back of LAURA Phase III trial results, which revealed it had extended median progression-free survival to more than three years.
Read more